PE79599A1 - Derivados de 5'-desoxicitidina - Google Patents

Derivados de 5'-desoxicitidina

Info

Publication number
PE79599A1
PE79599A1 PE1998000438A PE00043898A PE79599A1 PE 79599 A1 PE79599 A1 PE 79599A1 PE 1998000438 A PE1998000438 A PE 1998000438A PE 00043898 A PE00043898 A PE 00043898A PE 79599 A1 PE79599 A1 PE 79599A1
Authority
PE
Peru
Prior art keywords
refers
desoxi
group
compound
formula
Prior art date
Application number
PE1998000438A
Other languages
English (en)
Inventor
Nobuo Shimma
Kazuo Hattori
Tohru Ishikawa
Yasunori Kohchi
Hitomi Suda
Nobuhiro Oikawa
Hideo Ishitsuka
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE79599A1 publication Critical patent/PE79599A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA (I), DONDE R1 ES H O UN GRUPO FACILMENTE HIDROLIZABLE; R2 ES H o -CO-OR4, R4 ES UN GRUPO HIDROCARBONADO C1-C15 SATURADO O INSATURADO O UN GRUPO DE FORMULA -(CH2)nY; "Y" ES CICLOHEXILO O FENILO; n ES 0-4; R3 ES H, Br, I, CN, ALQUILO C1-C4 OPCIONALMENTE SUSTITUIDO CON HALOGENO, ENTRE OTROS. CUANDO R2 ES H, R3 NO ES H. SON COMPUESTOS PREFERIDOS 5`-DESOXI-5-ETINILCITIDINA; 5'-DESOXI-5-PROP-1-INILCITIDINA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE ADEMAS 3 Y 5 FLUORURACILO DE PREFERENCIA 5-FLUORO-1-(2-TETRAHIDROFURIL)URACILO, 1-(n-HEXILOXICARBONIL)-5-FLUORURACILO, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCESO PARA LA PREPARACION. EL COMPUESTO I PUEDE SER UTIL PARA TRATAR TUMORES
PE1998000438A 1997-06-02 1998-06-01 Derivados de 5'-desoxicitidina PE79599A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97108791 1997-06-02

Publications (1)

Publication Number Publication Date
PE79599A1 true PE79599A1 (es) 1999-08-25

Family

ID=8226859

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000438A PE79599A1 (es) 1997-06-02 1998-06-01 Derivados de 5'-desoxicitidina

Country Status (33)

Country Link
US (2) US6114520A (es)
JP (1) JP3081185B2 (es)
KR (1) KR100312899B1 (es)
CN (1) CN1197871C (es)
AR (1) AR012878A1 (es)
AT (1) ATE440854T1 (es)
AU (1) AU746170B2 (es)
BR (1) BR9801744A (es)
CA (1) CA2237368C (es)
CO (1) CO4940436A1 (es)
CZ (1) CZ295706B6 (es)
DE (2) DE69841086D1 (es)
ES (2) ES2329428T3 (es)
FR (1) FR2763953B1 (es)
GB (1) GB2325931B (es)
HR (1) HRP980290A2 (es)
HU (1) HU227852B1 (es)
ID (1) ID19801A (es)
IL (1) IL124661A0 (es)
IT (1) ITMI981196A1 (es)
MA (1) MA26503A1 (es)
MY (1) MY128985A (es)
NO (1) NO316609B1 (es)
NZ (1) NZ330360A (es)
PE (1) PE79599A1 (es)
PL (1) PL192832B1 (es)
RS (1) RS50010B (es)
RU (1) RU2238278C2 (es)
SA (1) SA98190103B1 (es)
SG (1) SG66466A1 (es)
TR (1) TR199800988A2 (es)
TW (1) TW584636B (es)
ZA (1) ZA984478B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030119724A1 (en) * 1995-11-22 2003-06-26 Ts`O Paul O.P. Ligands to enhance cellular uptake of biomolecules
DK1057831T3 (da) * 1999-05-26 2005-01-31 Hoffmann La Roche Fremgangsmåde til fremstilling af vinylpyrimidinderivater
WO2002043771A2 (en) 2000-12-01 2002-06-06 Cell Works Inc. Conjugates of glycosylated/galactosylated peptide
JP2008521930A (ja) * 2004-12-03 2008-06-26 アドヘレックス テクノロジーズ， インコーポレイテッド ５−ｆｕおよび５−ｆｕプロドラッグと併用してｄｐｄ阻害物質を投与するための方法
US20060161076A1 (en) * 2005-01-06 2006-07-20 Diamics, Inc. Systems and methods for collection of cell clusters
US20060189893A1 (en) * 2005-01-06 2006-08-24 Diamics, Inc. Systems and methods for detecting abnormal cells
US8058261B2 (en) * 2006-07-24 2011-11-15 Taiho Pharmaceutical Co., Ltd. 3′-ethynylcytidine derivative
US8741858B2 (en) 2007-09-21 2014-06-03 Zhongxu Ren Oligomer-nucleoside phosphate conjugates
KR101013312B1 (ko) * 2007-11-19 2011-02-09 한미홀딩스 주식회사 카페시타빈의 제조방법 및 이에 사용되는 β-아노머가강화된 트리알킬카보네이트 화합물의 제조방법
CN101469008B (zh) * 2007-12-29 2013-08-07 上海特化医药科技有限公司 卡培他滨羟基衍生物、其制备方法和用于制备卡培他滨
WO2009082844A1 (fr) * 2007-12-28 2009-07-09 Topharman Shanghai Co., Ltd Dérivé hydroxyle de la capécitabine, ses procédés de préparation et ses utilisations pour préparer la capécitabine
WO2009094847A1 (fr) * 2007-12-28 2009-08-06 Topharman Shanghai Co., Ltd. Dérivé hydroxyle de capécitabine, procédés de préparation et d' utilisation de la capécitabine
WO2009082846A1 (fr) * 2007-12-28 2009-07-09 Topharman Shanghai Co., Ltd. Dérivé hydroxyle de la capécitabine, ses procédés de préparation et ses utilisations pour préparer la capécitabine
DK2276774T3 (en) 2008-03-14 2016-11-28 Retrotope Inc Drugs that modulate genome methylation.
WO2010063080A1 (en) 2008-12-05 2010-06-10 Commonwealth Scientific And Industrial Research Organisation Amphiphile prodrugs
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
JP2013508293A (ja) * 2009-10-14 2013-03-07 アドヘレックス テクノロジーズ， インコーポレイテッド ５−ｆｕ又はそのプロドラッグと、ｄｐｄ阻害剤との組合せに付随した神経毒性の処置
CN104926890B (zh) * 2015-06-04 2018-04-03 新乡学院 一种1,2‑o‑二乙酰基‑3,5‑o‑二苯甲酰基核糖的合成方法
PE20210367A1 (es) 2018-02-02 2021-02-26 Maverix Oncology Inc Conjugados de farmacos de molecula pequena de monofosfato de gemcitabina
CN113321694A (zh) * 2021-06-22 2021-08-31 药康众拓(江苏)医药科技有限公司 N4-羟基胞苷衍生物及其制备方法和用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5726278B2 (es) * 1973-03-13 1982-06-03
GB1561290A (en) * 1975-10-16 1980-02-20 Nyegaard & Co As Pyrimid - 2 - ones
US4071680A (en) * 1976-12-20 1978-01-31 Hoffmann-La Roche Inc. 5'-Deoxy-5-fluoropyrimidine nucleosides
CH633810A5 (en) * 1978-01-01 1982-12-31 Hoffmann La Roche Novel nucleosides and process for their preparation
US4328229A (en) * 1978-03-29 1982-05-04 Taiho Pharmaceutical Company Limited Anti-cancer composition for delivering 5-fluorouracil to cancer tissues
JPS5677226A (en) * 1979-11-27 1981-06-25 Taiho Yakuhin Kogyo Kk Antitumorigenic agent
WO1985001871A1 (en) * 1983-10-26 1985-05-09 Greer Sheldon B Method and materials for sensitizing neoplastic tissue to radiation
US5736531A (en) * 1987-10-28 1998-04-07 Pro-Neuron, Inc. Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
CA1327358C (en) * 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives
GB9020930D0 (en) * 1990-09-26 1990-11-07 Wellcome Found Pharmaceutical combinations
EP0543015B1 (en) * 1991-05-27 1998-11-11 Taiho Pharmaceutical Co., Ltd. Composition, method and kit for potentiating antitumor activity and for curing tumor
DE4123520A1 (de) * 1991-07-16 1993-01-21 Inst Molekularbiologie Ak Mittel zur regeneration des blutbildes durch foerderung der leukozytenproliferation
TW254946B (es) * 1992-12-18 1995-08-21 Hoffmann La Roche
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
AU6081294A (en) * 1993-05-14 1994-12-12 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
ATE160571T1 (de) * 1993-09-14 1997-12-15 Merrell Pharma Inc 5-(1-fluorovinyl)-1h-pyrimidin-2,4-dion-derivat als antineoplastische mittel
US5476932A (en) * 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
TR199701435T1 (xx) * 1995-05-26 1998-03-21 F. Hoffmann-La Roche Ag İnterleukin ve pirimidin nükleositlerinin kompozisyonları

Also Published As

Publication number Publication date
IL124661A0 (en) 1998-12-06
RU2238278C2 (ru) 2004-10-20
JPH10330395A (ja) 1998-12-15
CO4940436A1 (es) 2000-07-24
CA2237368C (en) 2009-03-03
TR199800988A3 (tr) 1998-12-21
SA98190103B1 (ar) 2006-04-18
KR19990006547A (ko) 1999-01-25
CN1197871C (zh) 2005-04-20
NZ330360A (en) 1999-03-29
FR2763953A1 (fr) 1998-12-04
HU9801256D0 (en) 1998-07-28
CN1201037A (zh) 1998-12-09
AU746170B2 (en) 2002-04-18
US6114520A (en) 2000-09-05
HU227852B1 (en) 2012-05-02
NO316609B1 (no) 2004-03-08
ZA984478B (en) 1998-12-02
HRP980290A2 (en) 1999-04-30
ITMI981196A1 (it) 1999-11-29
ID19801A (id) 1998-08-06
SG66466A1 (en) 1999-07-20
GB2325931A (en) 1998-12-09
HUP9801256A2 (hu) 1999-05-28
MA26503A1 (fr) 2004-12-20
US6211166B1 (en) 2001-04-03
AR012878A1 (es) 2000-11-22
PL326604A1 (en) 1998-12-07
KR100312899B1 (ko) 2002-03-08
CZ167598A3 (cs) 1998-12-16
NO982473L (no) 1998-12-03
YU22598A (sh) 2001-12-26
ES2329428T3 (es) 2009-11-25
GB2325931B (en) 2001-07-25
PL192832B1 (pl) 2006-12-29
BR9801744A (pt) 2000-03-21
CA2237368A1 (en) 1998-12-02
TW584636B (en) 2004-04-21
DE69841086D1 (de) 2009-10-08
ES2142763B1 (es) 2001-04-01
ATE440854T1 (de) 2009-09-15
HUP9801256A3 (en) 2004-03-01
DE19823484A1 (de) 1998-12-03
NO982473D0 (no) 1998-05-29
RS50010B (sr) 2008-09-29
MY128985A (en) 2007-03-30
FR2763953B1 (fr) 2005-01-07
TR199800988A2 (xx) 1998-12-21
JP3081185B2 (ja) 2000-08-28
CZ295706B6 (cs) 2005-10-12
GB9811762D0 (en) 1998-07-29
AU6798598A (en) 1998-12-03
ES2142763A1 (es) 2000-04-16

Similar Documents

Publication Publication Date Title
PE79599A1 (es) Derivados de 5'-desoxicitidina
AR005706A1 (es) Inhibidores egfr de 4-aminoquinzolina, procedimiento para su obtencion, composicion farmaceutica que los contiene, uso de los mismos para lapreparacion de un medicamento util como agente antineoplasico
AR012660A1 (es) Uso de compuestos de quinazolina para la manufactura de un medicamento util para el tratamiento de enfermedades poliquisticas del rinon.
KR880000400A (ko) 융합된 사이클릭 아제핀-2-온 유도체 및 그의 제조방법
KR950005308A (ko) 직장투여용 조성물
ES2059313T3 (es) Peptidilaminodioles.
KR870003974A (ko) 비시클로 치환된 페닐아세토니트릴 유도체
CO5040216A1 (es) Agonistas de adenosina a 1, proceso para su preparacion y composiciones farmaceuticas que los contienen
EA199800909A1 (ru) Тригидрат мезилата 5-(2-(4-(1,2-бензизотиазол-3-ил)пиперазин-1-ил)этил)-6-хлор-1,3-дигидро-2н-индол-2-она, фармацевтическая композиция и способ лечения психического расстройства
AR006720A1 (es) Un compuesto derivado de azahexano heterociclico, su uso para la preparacion de una composicion farmaceutica, procedimiento para prepararlo y una composicion farmaceutica que lo comprende
ES2173172T3 (es) Derivados de 1,3-dihidroindol-2-ona sustituidos en 3 por un grupo nitrogenado como agonistas y/o antagonistas de la vasopresina y/o de la octocina.
PT99436A (pt) Processo para a preparacao de derivados de amino-sulfonil-carbamatos e de com- posicoes farmaceuticas que os contem
KR900018098A (ko) 피리돈 카르복실산과 항균제
KR880009922A (ko) 프롤리날 유도체
PE20001084A1 (es) Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas
PT911331E (pt) Compostos de dibenzoxazepina substituidos composicoes farmaceuticas e metodos de utilizacao
CS621987A2 (en) Coating composition
CO5180605A1 (es) Compuestos de indol
KR890009867A (ko) 비 펩타이드성 레닌 억제제
EA200100297A1 (ru) Моногидрат гидробромида элетриптана
KR920701120A (ko) 치환된 비시클로헵탄디온 유도체
ATE163850T1 (de) Pharmazeutische zusammensetzungen von 5ht1 agonistischen alkyl sulphonamidenfür rektale verabreichungen
KR900012903A (ko) 피롤리딘 화합물 및 약제학적 용도
ATE44648T1 (de) Antihypertensives kombinationspraeparat.
KR880002868A (ko) 피리도 피리미딘 디온

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed